Partnership with QIMR Berghofer targets oesophageal cancer
Filed with ASX · · 2 pages · English
Proteomics International and QIMR Berghofer Institute partner to target oesophageal cancer Highlights Proteomics International partners with QIMR Berghofer Medical Research Institute (QIMR Berghofer) to improve detection of oesophageal adenocarcinoma, the most common oesophageal cancer. The Partnership will use the Promarker™ platform with QIMR Berghofer biomarkers to develop a simple blood te
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- June 2020 Quarterly Activities Report and Appendix 4C
- PromarkerD Intellectual Property portfolio expands
- Appendix 3Y - Directors on-market purchase of shares
- Big pharma clinical study validates PromarkerD kidney test
- Updated Investor Presentation
Later from Proteomics International Laboratories
- First distribution agreement for PromarkerD immunoassay
- Proteomics International raises $6m in successful Placement
- September 2020 Quarterly Activities Report and Appendix 4C
- Completion of Placement and Appendix 2A
- Proteomics receives $1.1 million in R&D tax incentive
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories